Universal Medical Industry


Universal Medical Industry
Concise Prescribing Info
Nicardipine HCl
Short-term treatment of HTN when oral therapy is not feasible or not desirable.
Dosage/Direction for Use
Slow continuous IV infusion at a conc of 0.1 mg/mL. Gradual reduction in BP Initially 50 mL/hr (5 mg/hr). If desired BP reduction is not achieved at this dose, infusion rate may be increased by 25 mL/hr (2.5 mg/hr) 15 min or every 5 min for more rapid BP reduction up to a max of 150 mL/hr. Following achievement of the BP goal, the infusion rate should be decreased to 30 mL/hr (3 mg/hr). Hypotension or tachycardia Infusion may be restarted at low doses eg, 30-50 mL/hr (3-5 mg/hr) & adjusted to maintain desired BP when BP has stabilized.
Hypersensitivity. History of acute heart failure, advanced aortic stenosis. Neonates.
Special Precautions
CHF or impaired hepatic or renal function. Coronary ischemia. Increased angina upon initiation of therapy. Monitor BP during & after infusion. Avoid abrupt or excessive reduction in BP during therapy. Pregnancy & lactation. Childn < 2 yr.
Adverse Reactions
Dizziness, flushing, headache, hypotension, peripheral oedema, tachycardia & palpitations. Nausea & other GI disturbances, increased micturition frequency, lethargy, eye pain, visual disturbances & mental depression.
Drug Interactions
Additive/synergistic effects w/ β-blockers. Increased levels & toxicity of cyclosporine. Increased serum conc w/ cimetidine & grapefruit juice. Therapeutic effects may be decreased w/ rifampin.
MIMS Class
ATC Classification
C08CA04 - nicardipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Nidepine infusion 1 mg/mL
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in